7:41 PM ET
Earnings Call
▶ Call
Gilead Sciences Earnings Call: Key Takeaways
Gilead delivered record 16% base business growth driven by HIV and Oncology, though management faces a significant $1.5 billion revenue headwind in 2028 due to Medicare price setting for Biktarvy.
- Call
- Oct 29, 2026, 4:30 PM ET